Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia

INTRODUCTION: Gocovri, a bedtime-administered delayed-release/extended-release capsule formulation of amantadine, is the only drug approved by the US Food and Drug Administration as levodopa-adjunctive therapy for the treatment of OFF episodes and/or dyskinesia in Parkinson’s disease (PD). Part II o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Mehta, Shyamal H., Kremens, Daniel, Chernick, Dustin, Formella, Andrea E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571461/
https://www.ncbi.nlm.nih.gov/pubmed/34024025
http://dx.doi.org/10.1007/s40120-021-00256-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571461/
https://www.ncbi.nlm.nih.gov/pubmed/34024025
http://dx.doi.org/10.1007/s40120-021-00256-1

Ejemplares similares